Education
About Us
Working with TipRanks
Follow Us
Vera Therapeutics (VERA)
NASDAQ:VERA
Total Valuation
Vera Therapeutics has a market cap or net worth of $1.36B. The enterprise value is $1.97B.
Market Cap$1.36B
Enterprise Value$1.97B
Share Statistics
Vera Therapeutics has 63.77M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding63.77M
Owned by Insiders13.61%
Owned by Instutions0.10%
Financial Efficiency
Vera Therapeutics’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -26.46%.
Return on Equity (ROE)-26.36%
Return on Assets (ROA)-23.20%
Return on Invested Capital (ROIC)-26.46%
Return on Capital Employed (ROCE)-26.52%
Revenue Per Employee$0
Profits Per Employee-$1,358,464.286
Employee Count112
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Vera Therapeutics is -15.38. Vera Therapeutics’s PEG ratio is -0.69.
PE Ratio-15.38
PS Ratio0.00
PB Ratio4.05
Price to Fair Value4.05
Price to FCF-17.25
Price to Operating Cash Flow-17.37
PEG Ratio-0.69
Income Statement
In the last 12 months, Vera Therapeutics had revenue of $0.00 and earned -$152.15M in profits. Earnings per share was -$2.88.
Revenue$0.00
Gross Profit$952.00K
Operating Income-$167.17M
Pretax Income-$152.15M
Net Income-$152.15M
EBITDA-145.40M
Earnings Per Share (EPS)-2.88
Cash Flow
In the last 12 months, operating cash flow was -$134.68M and capital expenditures -$972.00K, giving a free cash flow of -$135.65M billion.
Operating Cash Flow-$134.68M
Free Cash Flow-$135.65M
Free Cash Flow per Share-$2.13
Dividends & Yields
Vera Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-5.80%
Earnings Yield-6.50%
Stock Price Statistics
Beta1.85
52-Week Price Change-45.59%
50-Day Moving Average27.16
200-Day Moving Average37.17
Relative Strength Index (RSI)37.24
Average Volume (3m)927.59K
Important Dates
Vera Therapeutics upcoming earnings date is May 8, 2025, Before Open.
Last Earnings DateMar 20, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Vera Therapeutics as a current ratio of 25.67, with Debt / Equity ratio of 0.09
Current Ratio25.67
Quick Ratio25.67
Debt to Market Cap0.02
Net Debt to EBITDA0.23
Interest Coverage Ratio21.92
Taxes
In the past 12 months, Vera Therapeutics has paid -$994.28K in taxes.
Income Tax-$994.28K
Effective Tax Rate<0.01%
Enterprise Valuation
Vera Therapeutics EV to EBITDA ratio is -13.77, with an EV/FCF ratio of -16.97.
EV to Sales0.00
EV to EBITDA-13.77
EV to Free Cash Flow-16.97
EV to Operating Cash Flow-17.09
Balance Sheet
Vera Therapeutics has $640.85M in cash and marketable securities with $54.64M in debt, giving a net cash position of -$586.21M billion.
Cash & Marketable Securities$640.85M
Total Debt$54.64M
Net Cash-$586.21M
Net Cash Per Share-$9.19
Tangible Book Value Per Share$10.43
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Vera Therapeutics is $67.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$67.20
Price Target Upside215.64%
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast
EPS Growth Forecast-20.03%